StockData

Novavax vs Vir Biotechnology

NVAX and VIR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NVAX and VIR compare

Vir Biotechnology is the larger company, worth 1.2 times as much as Novavax ($1.6B against $1.3B).

Vir Biotechnology grew revenue faster over the last twelve months (1496% versus −61.6% for Novavax).

Novavax keeps more of each dollar of sales as profit, with a net margin of −59.9% compared with −83.0% at Vir Biotechnology.

Vir Biotechnology scores higher on the StockData Score (11 against 4 for Novavax), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNVAXVIR
Size and price
Market cap$1.3B$1.6B
Share price$7.96$9.25
Change, 1 year14.2%64.3%
Change, 5 years−96.3%−74.3%
Beta (5Y)1.720.80
Employees749367
StockData Score
Total score411 (better)
Valuation score13 (better)
Growth score11
Performance score12 (better)
Health score15 (better)
Dividend score00
Valuation
P/S3.2× (better)5.2×
P/B–1.6×
FCF yield–−13.0%
Fair value–$13.31
Margin of safety–30.5%
Growth
Revenue growth (TTM)−61.6%1496% (better)
Revenue growth, 5Y average18.8% (better)−2.1%
Net income growth (TTM)−159%–
EPS growth (TTM)−168%–
Profitability
Gross margin78.6%–
Operating margin−56.6% (better)−92.4%
Net margin−59.9% (better)−83.0%
FCF margin–−67.1%
Return on equity–−26.1%
Return on invested capital–−55.2%
Financial health
Debt / equity–0.00
Interest coverage−10.7×–
Current ratio2.336.04 (better)
Altman Z-score−5.922.57 (better)
Piotroski F-score6 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions71.2%86.6%
Held by insiders9.2%17.1%
Insider net buying, 12 months–−$4.0M
Superinvestors holding1–
Short interest, % of float30.9%12.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.